Now two documentaries are set to reveal more about how the company raised money from investors in what turned out to be one of the biggest biotech scams in history. Holmes and Balwani still deny ...

Stewart was convicted of conspiracy, obstruction of justice and making false statements to federal investigators ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

Commissions do not affect our editors' opinions or evaluations. Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how ...

Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...

But one of the most powerful aspiring entrants, Novo Nordisk, may not be as intimidating for the biotech as it once was. Novo's molecule semaglutide (commonly known by the trade names Ozempic and ...

Bright Minds Biosciences, which until this week had a lightly traded stock that traded at just over $1, tumbled in premarket trade on Wednesday following a meteoric rise. Bright Minds shares DRUG ...

Andreas Föller outlines the different management skills needed by growing biotechnology companies. The founder of a successful public biotechnology company once told me that the secret to his ...

Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary ... African-born billionaire doctor and biotech entrepreneur, purchased the paper ...

The biotech exited stealth with $100 million in funding and then added $150 million in a series B round last year. Last year, Vertex paid Septerna $47.5 million for a licensing deal for an ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see the commercial-stage company adopt the biotech’s identity. The ...